GHENT, Belgium, 7 April 2015 - Ablynx [Euronext Brussels: ABLX; OTC ABYLY] today announced the publication of its 2014 Annual Report which can now be downloaded from the Company's new corporate website www.ablynx.com:
http://www.ablynx.com/ as a PDF file. It can also be viewed as an online html version:
http://issuu.com/ontwerpbureausoon/docs/2015-ablynx-report-en-issuu_0770e06cf2ae6f?e=1365425/12210018.
About Ablynx
Ablynx:
http://www.ablynx.com/ is a biopharmaceutical company engaged in the development of Nanobodies®:
http://www.ablynx.com/technology-innovation/understanding-nanobodies/, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 30 proprietary and partnered programmes:
http://www.ablynx.com/rd-portfolio/overview/ in development in various therapeutic areas including inflammation, haematology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Merck & Co., Inc, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com:
http://www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com:
mailto:edwin.moses@ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com:
mailto:marieke.vermeersch@ablynx.com%20
Follow us on Twitter @AblynxABLX
Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Jonathan Birt, Amber Bielecka, Lindsey Neville
t: +44 203 709 5700
e: ablynx@consilium-comms.com:
mailto:ablynx@consilium-comms.com
http://hugin.info/137912/R/1909236/680532.pdf
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire